α-Synuclein-IN-21
α-Synuclein-IN-21 is an α-synuclein (α-Syn) aggregation inhibitor with an IC50 of 1.6 μM. α-Synuclein-IN-21 stabilizes the secondary conformation of α-synuclein monomers, inhibits β-sheet formation, reduces oligonucleation during the aggregation lag phase, dissociates preformed aggregates, and blocks re-aggregation. α-Synuclein-IN-21 reduces α-synuclein inclusions in neuronal cells and scavenges ROS. α-Synuclein-IN-21 can be used for the research of Parkinson's disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2883627-65-2
- Formule: C22H15FN2O4
- Masse moléculaire:390.36
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform α-synuclein
More
Activité biologique
Description
In Vitro
α-Synuclein-IN-21 (Compound 3ec) (30 μM; 72 h) stabilizes the native random coil conformation of α-synuclein monomers and inhibits the formation of β-sheet-rich α-synuclein aggregates in vitro[1].
α-Synuclein-IN-21 (30 μM; 96 h) inhibits the entire process of α-synuclein aggregation, with its core effect exerted during the lag phase by reducing oligomer nuclei, which decreases the apparent fibril growth rate constant to 0.124 h−1[1].
α-Synuclein-IN-21 (30 μM; 88 h) inhibits the formation of large interconnected α-synuclein fibrils and reduces the size and density of aggregates[1].
α-Synuclein-IN-21 (30 μM; 0-88 h) depolymerizes preformed α-synuclein aggregates and inhibits their re-aggregation, with the highest efficacy when administered during the lag phase of aggregation[1].
α-Synuclein-IN-21 (10 μM; 38 h) inhibits the formation of α-synuclein inclusions in plasmid-transfected H4 cells[1].
α-Synuclein-IN-21 (10 μM; 30 min) scavenges up to 70% of reactive oxygen species in H4 cells[1].
α-Synuclein-IN-21 (1-100 μM; 24 h) exhibits low cytotoxicity in H4 and SH-SY5Y cells, maintaining over 85% cell viability even at concentrations up to 100 μM after 24 h of incubation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human neuroglioma H4 cells, human neuroblastoma SH-SY5Y cells
-
Concentration:1, 3, 10, 30, 100 μM
-
Incubation Time:24 h
-
Result:Showed no significant cytotoxicity in H4 or SH-SY5Y cells.
Maintained cell viabilities exceeding 85% even at the highest tested concentration of 100 μM.
Chemical Information
-
CAS No. 2883627-65-2
-
Masse moléculaire 390.36
-
Formule C22H15FN2O4
-
SMILES
O=C(C1=CC=C(C=C1)F)NC2=CC=C(C=C2)NC(/C=C/C(C(C=C3)=O)=CC3=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)